30 related articles for article (PubMed ID: 12566911)
1. A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : cancer and Leukemia Group B (CALGB) 80003.
Mamon HJ; Niedzwiecki D; Hollis D; Tan BR; Mayer RJ; Tepper JE; Goldberg RM; Blackstock AW; Fuchs CS;
Cancer; 2011 Jun; 117(12):2620-8. PubMed ID: 21656739
[TBL] [Abstract][Full Text] [Related]
2. Fixed-dose-rate gemcitabine: a viable first-line treatment option for advanced pancreatic and biliary tract cancer.
Milella M; Gelibter AJ; Pino MS; Bossone G; Marolla P; Sperduti I; Cognetti F
Oncologist; 2010; 15(2):e1-4. PubMed ID: 20189980
[TBL] [Abstract][Full Text] [Related]
3. A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy.
Grierson PM; Suresh R; Tan B; Pedersen KS; Amin M; Park H; Trikalinos NA; Liu J; Boice N; Brown A; Bansod S; Wang-Gillam A; Lim KH
Clin Cancer Res; 2023 Dec; 29(23):4733-4739. PubMed ID: 37801295
[TBL] [Abstract][Full Text] [Related]
4. A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301).
Spiliopoulou P; Kazmi F; Aroldi F; Holmes T; Thompson D; Griffiths L; Qi C; Parkes M; Lord S; Veal GJ; Harrison DJ; Coyle VM; Graham J; Jeffry Evans TR; Blagden SP
J Exp Clin Cancer Res; 2024 Apr; 43(1):100. PubMed ID: 38566164
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of neoadjuvant chemotherapy with gemcitabine plus oral S-1 for resectable pancreatic cancer.
Tajima H; Kitagawa H; Tsukada T; Nakanuma S; Okamoto K; Sakai S; Makino I; Furukawa H; Nakamura K; Hayashi H; Oyama K; Inokuchi M; Nakagawara H; Miyashita T; Fujita H; Itoh H; Takamura H; Ninomiya I; Fushida S; Fujimura T; Ohta T
Mol Clin Oncol; 2013 Jul; 1(4):768-772. PubMed ID: 24649244
[TBL] [Abstract][Full Text] [Related]
6. [Treatments of pancreatic cancer from the standpoint of medical oncology].
Furuse J; Ishii H; Nakachi K; Suzuki E; Shimizu S
Gan To Kagaku Ryoho; 2007 Jul; 34(7):997-1001. PubMed ID: 17637534
[TBL] [Abstract][Full Text] [Related]
7. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
[TBL] [Abstract][Full Text] [Related]
8. A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers.
Davis EJ; Griffith KA; Kim EJ; Ruch JM; McDonnell KJ; Zalupski MM
Am J Clin Oncol; 2018 Feb; 41(2):128-132. PubMed ID: 26535993
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
Gong JF; Zhang XD; Li J; Di LJ; Jin ML; Shen L
Ai Zheng; 2007 Aug; 26(8):890-4. PubMed ID: 17697554
[TBL] [Abstract][Full Text] [Related]
10. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer.
Hidalgo M; Castellano D; Paz-Ares L; Gravalos C; Diaz-Puente M; Hitt R; Alonso S; Cortes-Funes H
J Clin Oncol; 1999 Feb; 17(2):585-92. PubMed ID: 10080603
[TBL] [Abstract][Full Text] [Related]
11. Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancer.
Rauch DP; Maurer CA; Aebi S; Pampallona S; Friess H; Ludwig CU; Büchler MW; Borner MM
Oncology; 2001; 60(1):43-8. PubMed ID: 11150907
[TBL] [Abstract][Full Text] [Related]
12. Weekly gemcitabine and 24-hour infusional 5-fluorouracil in advanced pancreatic cancer: a phase I-II study.
Barone C; Cassano A; Corsi DC; Pozzo C; Longo R; Schinzari G; Quirino M; Battelli C; Basso M
Oncology; 2003; 64(2):139-45. PubMed ID: 12566911
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer.
Oettle H; Riess H
Cancer; 2002 Aug; 95(4 Suppl):912-22. PubMed ID: 12209671
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]